Bank of America
RLMD icon

Bank of America’s Relmada Therapeutics RLMD Stock Holding History

Bank of America’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.62M Buy
812,059
+686,118
+545% +$4.79M ﹤0.01% 3480
2026
Q1 		$877K Buy
125,941
+100,601
+397% +$476K ﹤0.01% 4580
2025
Q4 		$122K Buy
25,340
+25,077
+9,535% +$84K ﹤0.01% 5546
2025
Q3 		$528 Sell
263
-61
-19% -$59 ﹤0.01% 7579
2025
Q2 		$194 Sell
324
-13,392
-98% -$6.87K ﹤0.01% 7847
2025
Q1 		$3.7K Sell
13,716
-192,941
-93% -$64K ﹤0.01% 7262
2024
Q4 		$107K Sell
206,657
-1
-0% -$2 ﹤0.01% 6366
2024
Q3 		$670K Sell
206,658
-1,311
-0.6% -$4.25K ﹤0.01% 5306
2024
Q2 		$624K Sell
207,969
-2,607
-1% -$9.43K ﹤0.01% 5202
2024
Q1 		$979K Sell
210,576
-55
-0% -$265 ﹤0.01% 4948
2023
Q4 		$872K Sell
210,631
-2,904
-1% -$8.6K ﹤0.01% 5082
2023
Q3 		$641K Sell
213,535
-23,366
-10% -$69.4K ﹤0.01% 5144
2023
Q2 		$583K Buy
236,901
+199,567
+535% +$552K ﹤0.01% 5175
2023
Q1 		$84.4K Buy
37,334
+20,774
+125% +$71.6K ﹤0.01% 6313
2022
Q4 		$57.8K Buy
16,560
+2,695
+19% +$23.7K ﹤0.01% 6428
2022
Q3 		$513K Buy
13,865
+5,078
+58% +$141K ﹤0.01% 5377
2022
Q2 		$167K Buy
8,787
+2,051
+30% +$44.7K ﹤0.01% 6213
2022
Q1 		$182K Sell
6,736
-3,670
-35% -$75.9K ﹤0.01% 6525
2021
Q4 		$235K Sell
10,406
-1,875
-15% -$41.7K ﹤0.01% 6408
2021
Q3 		$322K Buy
12,281
+6,084
+98% +$163K ﹤0.01% 5961
2021
Q2 		$199K Sell
6,197
-1,581
-20% -$54.9K ﹤0.01% 6101
2021
Q1 		$274K Buy
7,778
+1,970
+34% +$68.9K ﹤0.01% 5808
2020
Q4 		$186K Sell
5,808
-1,751
-23% -$60.2K ﹤0.01% 5645
2020
Q3 		$284K Sell
7,559
-1,242
-14% -$48K ﹤0.01% 5080
2020
Q2 		$394K Sell
8,801
-5,161
-37% -$218K ﹤0.01% 4785
2020
Q1 		$476K Buy
+13,962
New +$563K ﹤0.01% 4533

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America's RLMD Position: Q2 2026 in Review

Bank of America increased its Relmada Therapeutics (RLMD) stake by 545% in Q2 2026, buying an estimated $4.79M and bringing the position to 812,059 shares worth $5.62M. The position accounts for ﹤0.01% of the portfolio, ranked #3480.

Bank of America first reported a position in RLMD in Q1 2020 and has held it in 26 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Bank of America held 812,059 shares of Relmada Therapeutics worth $5.62M as of Q2 2026.
  • Bank of America bought 686,118 Relmada Therapeutics shares in Q2 2026, an estimated $4.79M.
  • Relmada Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #3480 holding.
  • Bank of America first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.